Bioactivity | Lomedeucitinib (BMS-986322) is act by targeting receptor tyrosine protein kinase (TYK2). Lomedeucitinib can be used for the research of plaque psoriasis[1]. |
Name | Lomedeucitinib |
CAS | 2328068-29-5 |
Formula | C18H17D3N6O4S |
Molar Mass | 419.47 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Lomedeucitinib by Bristol-Myers Squibb for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval. |